- Home
- HYFM vs MYNZ Comparison
HYFM vs MYNZ Comparison
Compare HYFM & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFM | MYNZ |
|---|---|---|
| Founded | 1977 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 10.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYFM | MYNZ |
|---|---|---|
| Price | $1.37 | $0.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 25.0K | ★ 385.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $190,288,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $51.57 | $5.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $0.56 |
| 52 Week High | $5.80 | $5.69 |
Technical Indicators
Market Signals| Indicator | HYFM | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 35.54 | 25.41 |
| Support Level | $1.40 | $0.56 |
| Resistance Level | $1.48 | $1.37 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 7.54 |
Price Performance
Historical ComparisonAbout HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.